Interstitial lung diseases (ILDs) represent an extensive group of pulmonary disorders, characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, their etiology, clinical manifestations, diagnostic tools, and treatment options.
ILDs can be idiopathic or associated with various conditions such as connective tissue diseases, environmental exposures, and certain medications. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILDs. Other types include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, and hypersensitivity pneumonitis.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity for carbon monoxide.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs. It can identify characteristic patterns such as honeycombing, ground-glass opacities, and traction bronchiectasis. In certain cases, a lung biopsy may be necessary for definitive diagnosis.
Treatment of ILDs is primarily aimed at reducing inflammation and fibrosis, and managing symptoms. Corticosteroids and immunosuppressive agents are commonly used. For IPF, specific antifibrotic agents such as pirfenidone and nintedanib have shown efficacy. Lung transplantation may be considered for suitable candidates.
ILDs are complex disorders requiring a comprehensive diagnostic approach and individualized treatment strategies. Early recognition and appropriate management can significantly improve patient outcomes. Continued research is necessary to further our understanding of these diseases and develop more effective therapeutic options.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation